Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

This is a single arm, open-label, multi-center, phase I/II study to determine the engraftment, safety and clinical activity of allogeneic CARCIK-CD19 cells in adult and pediatric patients with relapsed/refractory mature B-cell neoplasia expected to express CD19 i.e. B-cell NHL and CLL. CARCIK-CD19 will be produced from the peripheral blood of an at least haploidentical familial donor.

Trial Details

NCT ID
NCT05869279
Phase
PHASE1 / PHASE2
Sponsor
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CARCIK-CD19
Locations (sample)
  • Bergamo, BG, Italy|45.69601,9.66721

Key Eligibility Criteria

  • criteria apply:
  • Able and willing to provide written informed consent and to comply with the study protocol according to International Conference on Harmonization (…
  • Ineligibility to commercially available CAR-T cells
  • Age limits: children (1-17 years old) and adults (≥18 years old)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →